{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:06:41Z","timestamp":1771510001300,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Oral migalastat has recently been approved for the treatment of Anderson-Fabry disease (FD) in patients aged \u226516\u2009years with amenable mutations on the basis of two phase III trials, FACETS and ATTRACT. However, with the introduction of migalastat into clinical practice, it is important to correctly identify the patients who may gain the most benefits from this therapy. Due to the relatively recent availability of migalastat, its role in clinical practice still has to be included in guidelines or recommendations. On these bases, a multidisciplinary group of Italian Experts in the treatment of FD has run the GALA project, with the aim to collect the opinions of expert physicians and to propose some starting points for an experience-based use of migalastat.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, although studies and data from longer-term follow-up with migalastat are still emerging, available evidence is consistent in showing that this molecule does represent a suitable therapy for the treatment of FD, in patients aged \u226516\u2009years and with amenable mutations. The use of migalastat as an oral option appears to be overall safe, and experience thus far indicates potential for improving quality of life, controlling GI symptoms, stabilizing renal function and reducing cardiac hypertrophy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Migalastat can be considered either as a first-line therapy \u2013 given its efficacy, extensive tissue penetration, convenient oral regimen, and the current limited therapeutic options available \u2013 or in patients on enzyme-replacement therapy (ERT) who experience side effects, with poor compliance to chronic i.v. therapy, or with clinical evidence of progression of the disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-1318-8","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T11:04:02Z","timestamp":1586257442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts"],"prefix":"10.1186","volume":"15","author":[{"name":"on behalf of the GALA Working Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Chimenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Nencini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"issue":"5","key":"1318_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/21678707.2018.1469978","volume":"6","author":"G Sunder-Plassmann","year":"2018","unstructured":"Sunder-Plassmann G, Schiffmann R, Nicholls K. Migalastat for the treatment of Fabry disease. Expert Opin Orphan Drugs. 2018;6(5):301\u20139.","journal-title":"Expert Opin Orphan Drugs"},{"key":"1318_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"issue":"9647","key":"1318_CR3","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008;372(9647):1427\u201335.","journal-title":"Lancet"},{"issue":"3","key":"1318_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1318_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccep.2015.03.014","volume":"7","author":"D Acharya","year":"2015","unstructured":"Acharya D, Doppalapudi H, Tallaj JA. Arrhythmias in Fabry cardiomyopathy. Card Electrophysiol Clin. 2015;7(2):283\u201391.","journal-title":"Card Electrophysiol Clin"},{"issue":"4","key":"1318_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"D Doheny","year":"2018","unstructured":"Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet. 2018;55(4):261\u20138.","journal-title":"J Med Genet"},{"issue":"2","key":"1318_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","volume":"41","author":"AB Burlina","year":"2018","unstructured":"Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A, et al. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in north East Italy. J Inherit Metab Dis. 2018;41(2):209\u201319.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1318_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"key":"1318_CR9","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0149-2918(08)80037-9","volume":"30","author":"A Mehta","year":"2008","unstructured":"Mehta A. Fabry disease \u2013 whom to treat and when. Clin Ther. 2008;30:S43\u20134.","journal-title":"Clin Ther"},{"issue":"13","key":"1318_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","volume":"95","author":"M Imbriaco","year":"2009","unstructured":"Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart. 2009;95(13):1103\u20137.","journal-title":"Heart"},{"issue":"2","key":"1318_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE. Ortiz A4, Svarstad E5, Warnock DG, et al. screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2017;91(2):284\u201393.","journal-title":"Kidney Int"},{"issue":"9","key":"1318_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","volume":"103","author":"A Mehta","year":"2010","unstructured":"Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, et al. Fabry disease: a review of current management strategies. QJM. 2010;103(9):641\u201359.","journal-title":"QJM"},{"issue":"2","key":"1318_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1600-0404.2012.01661.x","volume":"126","author":"A Bersano","year":"2012","unstructured":"Bersano A, Lanfranconi S, Valcarenghi C, Bresolin N, Micieli G, Baron P. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta Neurol Scand. 2012;126(2):77\u201397.","journal-title":"Acta Neurol Scand"},{"key":"1318_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0076-6879(03)01069-3","volume":"363","author":"JQ Fan","year":"2003","unstructured":"Fan JQ, Ishii S. Cell-based screening of active-site specific chaperone for the treatment of Fabry disease. Meth Enzymol. 2003;363:412\u201320.","journal-title":"Meth Enzymol"},{"issue":"4","key":"1318_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"issue":"4","key":"1318_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430\u20138.","journal-title":"Genet Med"},{"issue":"6","key":"1318_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"key":"1318_CR18","volume-title":"Canadian Fabry Disease Treatment Guidelines","author":"S Sirrs","year":"2018","unstructured":"Sirrs S, Bichet DG, Iwanochko RM, Khan A, Moore D, Oudit G, West ML. Canadian Fabry Disease Treatment Guidelines 2018. Available at http:\/\/garrod.ca\/wp-content\/uploads\/2019\/04\/Canadian-Fabry-Treatment-Guidelines-2018-final.pdf."},{"key":"1318_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1750-1172-7-91","volume":"7","author":"DP Germain","year":"2012","unstructured":"Germain DP, Giugliani R, Hughes DA, Mehta A, Nicholls K, Barisoni L, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase a activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis. 2012;7:91.","journal-title":"Orphanet J Rare Dis"},{"key":"1318_CR20","doi-asserted-by":"publisher","first-page":"100494","DOI":"10.1016\/j.ymgmr.2019.100494","volume":"20","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Bichet DG, Benjamin E, Wu X, Giugliani R. The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease. Mol Genet Metab Rep. 2019;20:100494. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100494.","journal-title":"Mol Genet Metab Rep"},{"key":"1318_CR21","unstructured":"Mauer M, Warnock DG, Politei JM, Yoo H-W, Wanner C. Fabry registry annual report 2014. Genzyme, a Sanofi company, 2014:1\u201318."},{"issue":"2","key":"1318_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inherit Metab Dis. 2007;30(2):184\u201392.","journal-title":"J Inherit Metab Dis"},{"issue":"9706","key":"1318_CR23","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, et al. Fabry outcome survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet. 2009;374(9706):1986\u201396.","journal-title":"Lancet"},{"key":"1318_CR24","doi-asserted-by":"publisher","unstructured":"Germain DP, Nicholls K, Giugliani R, Bichet DG, Hughes DA, Barisoni LM, et al. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Genet Med. 2019. https:\/\/doi.org\/10.1038\/s41436-019-0451-z [Epub ahead of print].","DOI":"10.1038\/s41436-019-0451-z"},{"issue":"5","key":"1318_CR25","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cpt.1321","volume":"105","author":"J M\u00fcntze","year":"2019","unstructured":"M\u00fcntze J, Gensler D, Maniuc O, Liu D, Cairns T, Oder D, et al. Oral chaperone therapy migalastat for treating fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharmacol Ther. 2019;105(5):1224\u201333. https:\/\/doi.org\/10.1002\/cpt.1321 Epub 2019 Jan 13.","journal-title":"Clin Pharmacol Ther"},{"key":"1318_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.","journal-title":"Orphanet J Rare Dis"},{"key":"1318_CR27","doi-asserted-by":"publisher","unstructured":"Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019 Feb 6;19:100454. doi: https:\/\/doi.org\/10.1016\/jymgmr2019100454 eCollection 2019 Jun.","DOI":"10.1016\/jymgmr2019100454"},{"key":"1318_CR28","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","volume":"105","author":"B Sachdev","year":"2002","unstructured":"Sachdev B, Takenaka T, Teraguchi H, Lee P, McKenna WJ, Elliott PM. Prevalence of Anderson-Fabry disease in male patients with late-onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407\u201311.","journal-title":"Circulation"},{"issue":"9","key":"1318_CR29","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","volume":"110","author":"C Chimenti","year":"2004","unstructured":"Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110(9):1047\u201353.","journal-title":"Circulation"},{"issue":"7","key":"1318_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00259-015-3036-3","volume":"42","author":"C Nappi","year":"2015","unstructured":"Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, et al. First experience of simultaneous PET\/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2015;42(7):1025\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1318_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.118.008424","volume":"12","author":"A Camporeale","year":"2019","unstructured":"Camporeale A, Pieroni M, Pieruzzi F, Lusardi P, Pica S, Spada M, et al. Predictors of clinical evolution in prehypertrophic Fabry disease. Circ Cardiovasc Imaging. 2019;12(4):e008424.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"1318_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4250\/jcu.2016.24.4.257","volume":"24","author":"M Alkema","year":"2016","unstructured":"Alkema M, Spitzer E, Soliman OI, Loewe C. Multimodality imaging for left ventricular hypertrophy severity grading: a methodological review. J Cardiovasc Ultrasound. 2016;24(4):257\u201367.","journal-title":"J Cardiovasc Ultrasound"},{"issue":"4","key":"1318_CR33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/cge.12386","volume":"86","author":"A Pisani","year":"2014","unstructured":"Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, et al. The kidney in Fabry's disease. Clin Genet. 2014;86(4):301\u20139.","journal-title":"Clin Genet"},{"issue":"2","key":"1318_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000488121","volume":"43","author":"M Del Pino","year":"2018","unstructured":"Del Pino M, Andr\u00e9s A, Bernab\u00e9u A\u00c1, de Juan-Rivera J, Fern\u00e1ndez E, de Dios Garc\u00eda D\u00edaz J, et al. Fabry nephropathy: an evidence-based narrative review. Kidney Blood Press Res. 2018;43(2):406\u201321.","journal-title":"Kidney Blood Press Res"},{"key":"1318_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000369309","volume":"129","author":"C Tondel","year":"2015","unstructured":"Tondel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG, Svarstad E. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron. 2015;129:16\u201321.","journal-title":"Nephron"},{"key":"1318_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"DP Germain","year":"2006","unstructured":"Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539\u201348.","journal-title":"Genet Med"},{"issue":"1","key":"1318_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000493469","volume":"141","author":"E Riccio","year":"2019","unstructured":"Riccio E, Sabbatini M, Bruzzese D, Annicchiarico Petruzzelli L, Pellegrino A, Spinelli L, et al. On behalf of AFFIINITY group. Glomerular hyperfiltration: an early marker of nephropathy in Fabry disease. Nephron. 2019;141(1):10\u20137.","journal-title":"Nephron"},{"key":"1318_CR38","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet. 2015;52:860\u20136.","journal-title":"J Med Genet"},{"issue":"4","key":"1318_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"RD Lindeman","year":"1985","unstructured":"Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278\u201385.","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"1318_CR40","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/jmedgenet-2017-104826","volume":"54","author":"M Mauer","year":"2017","unstructured":"Mauer M, Sokolovskiy A, Barth JA, Castelli JP, Williams HN, Benjamin ER, et al. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment. J Med Genet. 2017;54(11):781\u20136.","journal-title":"J Med Genet"},{"issue":"suppl_1","key":"1318_CR41","doi-asserted-by":"publisher","first-page":"i347","DOI":"10.1093\/ndt\/gfy104.SP004","volume":"33","author":"R Schiffmann","year":"2018","unstructured":"Schiffmann R, Bichet D, Germain DP, Giugliani R, Hughes D, Nicholls K, et al. Effects of long-term migalastat treatment on renal function by baseline proteinuria in patients with Fabry disease. Nephrol Dial Transplant. 2018;33(suppl_1):i347\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1318_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ymgme.2018.08.014","volume":"125","author":"S K\u00f6rver","year":"2018","unstructured":"K\u00f6rver S, Vergouwe M, Hollak CEM, van Schaik IN, Langeveld M. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. Mol Genet Metab. 2018;125(3):205\u201316.","journal-title":"Mol Genet Metab"},{"issue":"19","key":"1318_CR43","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1212\/WNL.0000000000003913","volume":"88","author":"S Cocozza","year":"2017","unstructured":"Cocozza S, Pisani A, Olivo G, Sacc\u00e0 F, Ugga L, Riccio E, et al. Alterations of functional connectivity of the motor cortex in Fabry disease: an RS-fMRI study. Neurology. 2017;88(19):1822\u20139.","journal-title":"Neurology"},{"issue":"16","key":"1318_CR44","doi-asserted-by":"publisher","first-page":"e1379","DOI":"10.1212\/WNL.0000000000005330","volume":"90","author":"P Phyu","year":"2018","unstructured":"Phyu P, Merwick A, Davagnanam I, Bolsover F, Jichi F, Wheeler-Kingshott C, et al. Increased resting cerebral blood flow in adult Fabry disease: MRI arterial spin labeling study. Neurology. 2018;90(16):e1379\u201385.","journal-title":"Neurology"},{"key":"1318_CR45","doi-asserted-by":"publisher","first-page":"c3666","DOI":"10.1136\/bmj.c3666","volume":"341","author":"S Debette","year":"2010","unstructured":"Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666. https:\/\/doi.org\/10.1136\/bmj.c3666.","journal-title":"BMJ"},{"issue":"1","key":"1318_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/mt.2009.220","volume":"18","author":"R Khanna","year":"2010","unstructured":"Khanna R, Soska R, Lun Y, Feng J, Frascella M, Young B, et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther. 2010;18(1):23\u201333.","journal-title":"Mol Ther"},{"issue":"3","key":"1318_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.21606","volume":"41","author":"R Liguori","year":"2010","unstructured":"Liguori R, Di Stasi V, Bugiardini E, Mignani R, Burlina A, Borsini W, et al. Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve. 2010;41(3):409\u201312.","journal-title":"Muscle Nerve"},{"issue":"7","key":"1318_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180581","volume":"12","author":"R Liguori","year":"2017","unstructured":"Liguori R, Incensi A, de Pasqua S, Mignani R, Fileccia E, Santostefano M, et al. Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy. PLoS One. 2017;12(7):e0180581. https:\/\/doi.org\/10.1371\/journal.pone.0180581 eCollection 2017.","journal-title":"PLoS One"},{"issue":"6","key":"1318_CR49","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/mus.10497","volume":"28","author":"R Schiffmann","year":"2003","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003;28(6):703\u201310.","journal-title":"Muscle Nerve"},{"key":"1318_CR50","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","volume":"62","author":"MJ Hilz","year":"2004","unstructured":"Hilz MJ, Brays M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, ad, and Ab-nerve fibers in Fabry neuropathy. Neurology. 2004;62:1066\u201372.","journal-title":"Neurology"},{"issue":"1","key":"1318_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13023-018-0813-7","volume":"13","author":"R Schiffmann","year":"2018","unstructured":"Schiffmann R, Bichet DG, Jovanovic A, Hughes DA, Giugliani R, Feldt-Rasmussen U, et al. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018;13(1):68.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1318_CR52","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/ajmg.a.61105","volume":"179","author":"DA Hughes","year":"2019","unstructured":"Hughes DA, Nicholls K, Sunder-Plassmann G, Jovanovic A, Feldt-Rasmussen U, Schiffmann R, et al. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: experience from the phase 3 ATTRACT study. Am J Med Genet A. 2019 Jun;179(6):1069\u201373.","journal-title":"Am J Med Genet A"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1318-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-1318-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1318-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:31:50Z","timestamp":1617737510000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-1318-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-1318-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the co-authors have read the manuscript and approved its submission to \u201cOrphanet Journal of Rare Diseases\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CC has received travel assistance and honoraria for teaching from Shire and Amicus Therapeutics. SF has received travel assistance and honoraria for lecturing and for participating in advisory boards from Genzyme\/Sanofi, Shire, Amicus Therapeutics, Otsuka. AP has received travel assistance and honoraria for lecturing and for participating in advisory boards from Genzyme\/Sanofi, Shire, Amicus Therapeutics, Protalix. PN has received travel assistance and honoraria for lecturing and for participating in advisory boards from Shire, Genzyme\/Sanofi, and Amicus Therapeutics. FP has received travel assistance and honoraria for lecturing and for participating in advisory boards from Sanofi Genzyme, Shire-Takeda and Amicus Therapeutics. RM has received travel assistance and honoraria for lecturing and for participating in advisory boards from Sanofi Genzyme, Takeda, Amicus Therapeutics and Otsuka. MP has received travel assistance and honoraria for lecturing and for participating in advisory boards from Sanofi Genzyme, Takeda, Amicus Therapeutics and Otsuka.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}